Frédéric Triebel, MD Ph.D.Chief Scientific Officer & Chief Medical Officer
Frédéric Triebel, MD Ph.D., was the scientific founder of Immutep S.A. (2001) and served as the Scientific and Medical Director at Immutep from 2004. Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and in subsequent research identified the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996.
First trained as a clinical haematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 144 publications and 16 patents.
Deanne MillerChief Operating Officer, General Counsel & Company Secretary
Ms Miller has over 13 years of broad commercial experience, having held legal, investment banking, regulatory, and tax advisory positions, including Associate Director at Westpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima BioMed as General Counsel and Company Secretary in October 2012. Ms Miller holds a Bachelor of Laws (Hons) and Bachelor of Commerce from the University of Sydney. She is admitted as a solicitor in NSW and is a member of the Law Society of NSW.
Larisa Chisholm Director Industry Liaison and Development and Director of Intellectual Property
With a background in both science and business, Ms Chisholm has more than 20 years' experience working in the life science industry and has worked for Prima BioMed since 2003. Ms Chisholm's industry experience includes immunology, oncology, cell therapy, business development, intellectual property and stakeholder management.
Her role at Prima encompasses responsibility for existing and new industry alliances, the coordination of commercial support for business development and licensing activities and intellectual property portfolio responsibility.
Ms Chisholm has a Bachelor of Science (Hons) majoring in biochemistry and genetics and a Masters' Degree in Business Administration.
Christian MuellerDirector Clinical Development
Christian Mueller, MSc BBA, works in the field of clinical development of oncology drugs for more than a decade.
After finishing his studies at the Technical University Berlin with the Master of Science in Biotechnology he joined Medical Enzymes AG who has its focus on therapeutic enzymes for the treatment of cancer. As a project manager he was responsible for all deliverables of clinical phase I and II studies. Later he built up a clinical team and took over the responsibilities for the strategic clinical development of the lead compound. Since 2012 he worked with Ganymed Pharmaceuticals AG. Ganymed is developing ideal monoclonal antibodies in the field of immune oncology. As a Manager Clinical Research he was responsible for the clinical development program of the lead antibody and the setup and management of the clinical team. Most recently he successfully completed a multinational randomized phase II study with 200+ patients investigating the lead antibody as first line treatment in combination with chemotherapy in patients with advanced metastatic gastric cancer (publication during ASCO 2016). His efforts in the field of clinical development have led to several publications and patents.